https://scholars.lib.ntu.edu.tw/handle/123456789/523388
標題: | Marked elevation of liver transaminases after high-dose fluvastatin unmasks chronic hepatitis C: Safety and re-challenge | 作者: | Chen Y.-W. Lai H.-W. TZUNG-DAU WANG |
關鍵字: | Hepatitis C; Hyperlipidemia; Safety; Statin | 公開日期: | 2007 | 卷: | 16 | 期: | 3 | 起(迄)頁: | 163-167 | 來源出版物: | Acta Neurologica Taiwanica | 摘要: | The statins, 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, have emerged as the drugs of choice for patients with dyslipidemia and have been shown to reduce major cardiovascular adverse events in large-scale clinical trials for both primary and secondary prevention. Statins are generally safe; however, the results of clinical trials do demonstrate possibilities of significant adverse effects in liver and muscle. Moreover, the numbers from the trials may not reflect the real situation in daily practice because individuals at increased risk for hepatotoxicity are usually deliberately and carefully excluded in clinical trials. We presented an 85-year-old woman who had a marked elevation of ALT (up to 409 U/L) after treatment with fluvastatin 80 mg/day for 6 weeks. Hepatitis C was identified after this episode. The elevation of ALT resolved 10 weeks after discontinuation of fluvastatin. Re-institution of fluvastatin from 40 to 80 mg/day for 2 months only cause mild elevation of ALT. This case suggests that elevation of transaminases during statin therapy may not be solely ascribed to statins. Re-challenge with the same statin at lower doses or with other statins may help to identify the patients who can still be treated with drugs of this category. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-35048875811&partnerID=40&md5=bdabc6089c3ab3b560db80663404fabb https://scholars.lib.ntu.edu.tw/handle/123456789/523388 |
ISSN: | 1019-6099 | SDG/關鍵字: | amoxicillin; atorvastatin; clarithromycin; clopidogrel; esomeprazole; fluindostatin; glimepiride; irbesartan; liver enzyme; simvastatin; aged; anamnesis; artery occlusion; article; atherosclerosis; case report; clinical feature; dose response; drug dose increase; drug megadose; drug safety; drug withdrawal; female; follow up; Helicobacter infection; hepatitis C; human; hypertension; nuclear magnetic resonance imaging; side effect; treatment duration; vertigo; Aged; Aged, 80 and over; Alanine Transaminase; Drug Interactions; Fatty Acids, Monounsaturated; Female; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Liver |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。